J. Foley

发表

A G Protein-coupled Receptor for UDP-glucose*

J. Chambers, L. Macdonald, H. Sarau, 2000, The Journal of Biological Chemistry.

Antiinflammatory Activity in Animal Models Receptor That Demonstrates Antagonist of the Anaphylatoxin C3a Identification of a Selective Nonpeptide

McCafferty, J. Adams, K. Ward, 2001 .

Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.

H. Sarau, J. Foley, N. Aiyar, 2008, Bioorganic & medicinal chemistry letters.

Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists.

G. Warren, H. Sarau, J. Foley, 2005, Bioorganic & medicinal chemistry letters.

The neuromedin B receptor antagonist, BIM‐23127, is a potent antagonist at human and rat urotensin‐II receptors

H. Sarau, J. Foley, D. Behm, 2003, British journal of pharmacology.

The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems

H. Sarau, R. Ames, J. Foley, 2006, British journal of pharmacology.

Screening Orphan Receptors for Native Ligands

J. Culp, J. Chambers, H. Sarau, 2019, G Protein-Coupled Receptors.

Saccharomyces cerevisiae telomerase is an Sm small nuclear ribonucleoprotein particle

H. Sarau, J. Foley, N. Aiyar, 1999 .

Identification of an EDG7 variant, HOFNH30, a G-protein-coupled receptor for lysophosphatidic acid.

H. Sarau, R. Ames, J. Foley, 2000, Biochemical and biophysical research communications.

The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing

J. Foley, W. Rumsey, M. Salmon, 2011 .

Identification of a Potent, Selective Non-peptide CXCR2 Antagonist That Inhibits Interleukin-8-induced Neutrophil Migration*

R. Hertzberg, H. Sarau, J. Foley, 1998, The Journal of Biological Chemistry.

Inhibitors of protein kinase C selectively enhanced leukotriene D4-induced calcium mobilization in differentiated U-937 cells.

H. Sarau, J. Foley, S. Crooke, 1990, Cellular signalling.

Cloning, in Vitro Expression, and Functional Characterization of a Novel Human CC Chemokine of the Monocyte Chemotactic Protein (MCP) Family (MCP-4) That Binds and Signals through the CC Chemokine Receptor 2B*

H. Sarau, J. Foley, N. Elshourbagy, 1997, The Journal of Biological Chemistry.

The FASEB Journal express article 10.1096/fj.03-0170fje. Published online Novermber 3, 2003. Regulation of TNF-α and IFN-γ induced CXCL10

H. Sarau, J. Foley, A. Roshak, 2022 .

Association between leukotriene B4-induced phospholipase D activation and degranulation of human neutrophils.

H. Sarau, J. Foley, T. Torphy, 1993, Biochemical pharmacology.

Nonpeptidic urotensin‐II receptor antagonists I: in vitro pharmacological characterization of SB‐706375

David G. Behm, H. Sarau, J. Foley, 2005, British journal of pharmacology.

Cloning and pharmacological characterization of the cat urotensin-II receptor (UT).

H. Sarau, J. Foley, N. Aiyar, 2005, Biochemical pharmacology.

Leukotriene B4-induced homologous desensitization of calcium mobilization and phosphoinositide metabolism in U-937 cells.

H. Sarau, J. Foley, S. Crooke, 1988, The Journal of pharmacology and experimental therapeutics.

Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor.

H. Sarau, R. Ames, J. Foley, 2001, European journal of pharmacology.

Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function.

H. Sarau, J. Foley, J. White, 1997, The Journal of pharmacology and experimental therapeutics.

Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.

H. Sarau, J. Foley, F. Barone, 2002, The Journal of pharmacology and experimental therapeutics.

Mechanisms of leukotriene E4 partial agonist activity at leukotriene D4 receptors in differentiated U-937 cells.

H. Sarau, J. Foley, S. Crooke, 1989, The Journal of biological chemistry.

Inhibition of leukotriene D4-induced coronary vasoconstriction by leukotriene antagonists in the anesthetized dog.

H. Sarau, J. Foley, T. Torphy, 1987, The Journal of pharmacology and experimental therapeutics.

Chronic Models of Arthritis in the Rabbit Antagonist of CXCR2 Inhibits Acute and A Potent and Selective Nonpeptide

H. Sarau, J. Foley, L. Marshall, 2013 .

A Potent and Selective Nonpeptide Antagonist of CXCR2 Inhibits Acute and Chronic Models of Arthritis in the Rabbit1

H. Sarau, J. Foley, L. Marshall, 2002, The Journal of Immunology.

Identification of Potent, Selective Non-peptide CC Chemokine Receptor-3 Antagonist That Inhibits Eotaxin-, Eotaxin-2-, and Monocyte Chemotactic Protein-4-induced Eosinophil Migration*

H. Sarau, J. Foley, C. Imburgia, 2000, The Journal of Biological Chemistry.

2-Phenyl-4-quinolinecarboxamides: a novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor.

H. Sarau, J. Foley, A. Medhurst, 1996, Journal of medicinal chemistry.

Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.

J. D. Elliott, D. Veber, R. Hertzberg, 2004, Journal of medicinal chemistry.

Antiinflammatory Activity in Animal Models Receptor That Demonstrates Antagonist of the Anaphylatoxin C3a Identification of a Selective Nonpeptide

McCafferty, J. Adams, K. Ward, 2001 .

Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2

R. Tal-Singer, J. Foley, R. Mayer, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Tyrosine urea muscarinic acetylcholine receptor antagonists: achiral quaternary ammonium groups.

H. Sarau, J. Foley, Yonghui Wang, 2012, Bioorganic & medicinal chemistry letters.

Design, synthesis and structure-activity relationship of N-substituted tropane muscarinic acetylcholine receptor antagonists.

Zehong Wan, H. Sarau, J. Foley, 2012, Bioorganic & medicinal chemistry letters.

2' biaryl amides as novel and subtype selective M1 agonists. Part I: Identification, synthesis, and initial SAR.

C. Langmead, J. Foley, I. Forbes, 2010, Bioorganic & medicinal chemistry letters.

M3 muscarinic acetylcholine receptor antagonists: SAR and optimization of bi-aryl amines.

Zehong Wan, Dwight M. Morrow, H. Sarau, 2009, Bioorganic & medicinal chemistry letters.

Muscarinic acetylcholine receptor antagonists: SAR and optimization of tyrosine ureas.

Dwight M. Morrow, Wei-Chang Fu, H. Sarau, 2008, Bioorganic & medicinal chemistry letters.

Discovery of novel 8-azoniabicyclo[3.2.1]octane carbamates as muscarinic acetylcholine receptor antagonists.

J. Foley, K. Belmonte, Haibo Xie, 2007, Bioorganic & medicinal chemistry letters.

TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis.

J. Foley, N. Laping, J. Cottom, 2017, Blood advances.

Evidence that the receptor for C4a is distinct from the C3a receptor.

H. Sarau, R. Ames, J. Foley, 1997, Immunopharmacology.

Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils

H. Sarau, J. Foley, N. Elshourbagy, 1997, Journal of leukocyte biology.

Influx of extracellular calcium is required for the membrane translocation of 5-lipoxygenase and leukotriene synthesis.

H. Sarau, J. Foley, S. Hwang, 1991, Biochemistry.

Identification and characterization of leukotriene D4 receptors and signal transduction processes in rat basophilic leukemia cells.

H. Sarau, J. Foley, H. Wu, 1987, The Journal of biological chemistry.

Comparison of central and peripheral alpha1-adrenoceptors

H. Sarau, J. Foley, J. Hieble, 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.

Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.

H. Sarau, J. Foley, F. Barone, 2000, The Journal of pharmacology and experimental therapeutics.

Evidence that the proposed novel human "neurokinin-4" receptor is pharmacologically similar to the human neurokinin-3 receptor but is not of human origin.

D. Y. Wang, H. Sarau, J. Foley, 2000, Molecular pharmacology.

In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity.

H. Sarau, J. Foley, S. Van Horn, 1999, Prostaglandins, leukotrienes, and essential fatty acids.

N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.

J. D. Elliott, Wei-Chang Fu, H. Sarau, 2006, Bioorganic & medicinal chemistry letters.

The role of the anionic groups in the receptor binding of interleukin-8 antagonists

D. Veber, R. Hertzberg, H. Sarau, 1998, Letters in Peptide Science.

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes

T. Severson, L. Wessels, J. Foley, 2018, Haematologica.

Chimeric Receptors of the Human C3a Receptor and C5a Receptor (CD88)*

H. Sarau, R. Ames, J. Foley, 1999, The Journal of Biological Chemistry.

Leukotriene D4 Increases the Metabolism of an Inositol Tetrakisphosphate - Containing Phospholipid in U937 Cells

H. Sarau, J. Foley, S. Crooke, 1990 .

Leukotriene D4-induced homologous desensitization in basal and differentiated U-937 cells: characterization with the partial agonist leukotriene E4 and assessment of receptor reserve.

H. Sarau, J. Foley, S. Crooke, 1988, The Journal of pharmacology and experimental therapeutics.

(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.

H. Sarau, J. Foley, K. Sham, 1996, Journal of medicinal chemistry.

Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships.

H. Sarau, J. Foley, D. R. Jakas, 1993, Journal of medicinal chemistry.

Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors.

P. Grandi, I. Wall, James M. Woolven, 2021, Journal of medicinal chemistry.

3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.

Wei-Chang Fu, H. Sarau, J. Foley, 2007, Bioorganic & medicinal chemistry letters.

Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor.

K. Ward, H. Sarau, J. Foley, 2007, Bioorganic & medicinal chemistry letters.

Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists.

J. Foley, F. Blaney, M. Salmon, 2009, Journal of medicinal chemistry.

erratum: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

H. Sarau, R. Ames, J. Foley, 1999, Nature.

Molecular Cloning and Characterization of the Human Anaphylatoxin C3a Receptor*

R. Hertzberg, H. Sarau, R. Ames, 1996, The Journal of Biological Chemistry.

Human anaphylatoxin C4a is a potent agonist of the guinea pig but not the human C3a receptor.

H. Sarau, R. Ames, J. Foley, 1998, Journal of immunology.

Synthesis, resolution, absolute stereochemistry, and enantioselectivity of 3',4'-dihydroxynomifensine.

H. Sarau, J. Foley, C. Kaiser, 1984, Journal of medicinal chemistry.

PHARMACOLOGICAL CHARACTERIZATION OF THE CATECHOLAMINERGIC RECEPTORS REGULATING cAMP ACCUMULATION IN RAT STRIATUM

H. Sarau, J. Foley, P. Setler, 1979 .

Identification of a Selective Nonpeptide Antagonist of the Anaphylatoxin C3a Receptor That Demonstrates Antiinflammatory Activity in Animal Models

J. Adams, K. Ward, H. Sarau, 2001, The Journal of Immunology.

H. Sarau, J. Foley, F. Barone, 1995, Molecular and chemical neuropathology.

Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).

H. Sarau, J. Foley, A. Medhurst, 1999, Journal of medicinal chemistry.

Calmodulin-Binding Peptide PEP-19 Modulates Activation of Calmodulin Kinase II In Situ

H. Sarau, J. Foley, R. Johanson, 2000, The Journal of Neuroscience.

Identification and molecular characterization of rat CXCR3: receptor expression and interferon-inducible protein-10 binding are increased in focal stroke.

H. Sarau, R. Ames, J. Foley, 2000, Molecular pharmacology.

The mouse anaphylatoxin C3a receptor: molecular cloning, genomic organization, and functional expression.

H. Sarau, R. Ames, J. Foley, 1997, Journal of immunology.

Receptor for the Pain Modulatory Neuropeptides FF and AF Is an Orphan G Protein-coupled Receptor*

J. Chambers, H. Sarau, R. Ames, 2000, The Journal of Biological Chemistry.

Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1

J. Chambers, H. Sarau, R. Ames, 1999, Nature.

Optimized procedures for producing biologically active chemokines.

R. Ames, J. Foley, J. Fornwald, 2009, Protein expression and purification.

Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.

H. Sarau, J. Foley, N. Elshourbagy, 1997, The Journal of pharmacology and experimental therapeutics.

Synthesis and LTB4 receptor antagonist activities of the naturally occurring LTB4 receptor antagonist Leucettamine A and related analogues.

J. Boehm, H. Sarau, J. Foley, 1993, Journal of medicinal chemistry.

Pharmacological Characterization of GSK573719 (Umeclidinium): A Novel, Long-Acting, Inhaled Antagonist of the Muscarinic Cholinergic Receptors for Treatment of Pulmonary Diseases

H. Sarau, J. Foley, W. Rumsey, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Discovery of novel and long acting muscarinic acetylcholine receptor antagonists.

Dwight M. Morrow, Wei-Chang Fu, H. Sarau, 2008, Journal of medicinal chemistry.

A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma.

M. Wagner, J. Vestbo, H. Sarau, 2004, Pharmacogenetics.

Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.

J. Chambers, H. Sarau, R. Ames, 1999, Molecular pharmacology.

BacMam recombinant baculoviruses in G protein-coupled receptor drug discovery.

Thomas Kost, John Trill, Michael Romanos, 2004, Receptors & channels.

Salbutamol Up-regulates PDE4 Activity and Induces a Heterologous Desensitization of U937 Cells to Prostaglandin E2

H. Sarau, J. Foley, T. Torphy, 1995, The Journal of Biological Chemistry.

Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

H. Sarau, R. Ames, J. Foley, 1999, Nature.

Radioligand Binding and Functional Characterization of Recombinant Human NmU1 and NmU2 Receptors Stably Expressed in Clonal Human Embryonic Kidney-293 Cells

H. Sarau, J. Foley, N. Aiyar, 2004, Pharmacology.

Effects of scalaradial, a novel inhibitor of 14 kDa phospholipase A2, on human neutrophil function.

H. Sarau, J. Foley, L. Marshall, 1994, Biochemical pharmacology.

Metabolism of dog gastric mucosa. Levels of glycolytic, citric acid cycle and other intermediates.

G. Sachs, H. Sarau, J. Foley, 1977, The Journal of biological chemistry.

15-Acetylthioxy-furodysinin lactone, isolated from a marine sponge Dysidea, sp. is a potent agonist to human leukotriene B4 receptor.

H. Sarau, J. Foley, J. Westley, 1990, Prostaglandins.

Neuromedin Elicits Cytokine Release in Murine Th2-Type T Cell Clone D10.G4.1

H. Sarau, J. Foley, N. Aiyar, 2004, The Journal of Immunology.

(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.

H. Sarau, J. Foley, D. R. Jakas, 1993, Journal of Medicinal Chemistry.

Phorbol 12-myristate 13-acetate inhibition of leukotriene D4-induced signal transduction was rapidly reversed by staurosporine.

H. Sarau, J. Foley, S. Crooke, 1988, Biochemical and biophysical research communications.

Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.

Todd L Graybill, H. Sarau, J. Foley, 2009, Bioorganic & medicinal chemistry letters.

Metabolism of dog gastric mucosa. Nucleotide levels in parietal cells.

H. Sarau, J. Foley, G. Moonsammy, 1975, The Journal of biological chemistry.

Stimulation of leukotriene production and membrane translocation of 5-lipoxygenase by cross-linking of the IgE receptors in RBL-2H3 cells.

H. Sarau, J. Foley, S. Crooke, 1992, Biochemistry.

Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD.

Zehong Wan, H. Sarau, J. Foley, 2009, Bioorganic & medicinal chemistry letters.

Design, synthesis, and structure-activity relationship of tropane muscarinic acetylcholine receptor antagonists.

Zehong Wan, Wei-Chang Fu, H. Sarau, 2009, Journal of medicinal chemistry.

SB 209247, a high affinity LTB4 receptor antagonist demonstrating potent antiinflammatory activity.

H. Sarau, J. Foley, D. Schmidt, 1995, Advances in prostaglandin, thromboxane, and leukotriene research.

Oxazolidinones as novel human CCR8 antagonists.

Dwight M. Morrow, H. Sarau, J. Foley, 2007, Bioorganic & medicinal chemistry letters.

Transient activation of topoisomerase I in leukotriene D4 signal transduction in human cells.

H. Sarau, J. Foley, S. Crooke, 1990, The Biochemical journal.

Discovery of biphenyl piperazines as novel and long acting muscarinic acetylcholine receptor antagonists.

Zehong Wan, Dwight M. Morrow, H. Sarau, 2008, Journal of Medicinal Chemistry.

Cloning and characterization of a rabbit ortholog of human Gα16 and mouse Gα15

H. Sarau, R. Ames, J. Foley, 1999 .